###### Strengths and limitations of this study

-   This is the first concise depiction of the worldwide scientific productivity related to respiratory syncytial virus, which was assessed by geographical, chronological and socioeconomic criteria.

-   The NewQIS (New Quality and Quantity Indices in Science) platform combines scientometric methods and 'density equalizing mapping projections' to evaluate the scientific output regarding quantitative and qualitative aspects, geographical and chronological developments, existing research networks and socioeconomic benchmarks in a reliable and standardised way.

-   Since the Web of Science has a preference for English journals, we have to acknowledge a language bias associated with our analysis.

-   Citation-based parameters were assessed, which have limitations since these rather reflect the recognition of the research in the scientific community than truly measure quality.

Introduction {#s1}
============

The human respiratory syncytial virus (RSV) is the predominant viral agent affecting the respiratory tract worldwide.[@R1] It is associated with 64 million infections that occur primarily in children under 5 years.[@R3] RSV belongs to the Paramyxoviridae family and is a negative-sense, non-segmented, single-stranded RNA virus, which is mostly transmitted by droplets.[@R4] RSV causes bronchiolitis, pneumonia, bronchitis and croup. It is linked to recurrent wheezing and paediatric asthma.[@R5] There is no definitive treatment for RSV-related conditions. Although the development of effective and safe vaccines has remained unsuccessful to date, the variety of candidate vaccines is constantly growing in the last years.[@R7] One prophylactic agent is commercially available, the neutralising anti-RSV antibody palivizumab. Its use is limited to preterm babies, chronic lung disease of prematurity and infants with congenital heart disease.[@R8]

RSV-associated morbidity and mortality depends on many factors such as the geographic location, climate patterns, genetic susceptibility, socioeconomic factors and local virus strains.[@R3] The percentage of children having contracted RSV by their second year of life approaches 100%.[@R9] In the USA, over 2 million children aged 5 years and below need medical attention to treat their RSV infection every year.[@R11] On average, 0.3% of these children and 0.7% of infants younger than 6 months require hospitalisation.[@R11] The general RSV mortality rate in this demographic varies between 0% and 33%.[@R10] Worldwide, up to 199 000 children die due to RSV infections. Ninety-nine per cent of these deaths occur in in developing countries,[@R3] hence RSV represents a substantial burden for community health in these nations. According to WHO field studies in 10 developing countries, RSV causes 70% of all acute respiratory tract infections in children below 5 years of age.[@R12] Here, the virus is identified in about 15%--40% of the hospitalised children with pneumonia or bronchiolitis.[@R13] RSV epidemics occur during rainy seasons in tropical climates and during the winter months in temperate zones.[@R4] Both virus strains, RSV-A and RSV-B, cocirculate during respective outbreaks . The A subtype is typically associated with more severe disease.[@R14] Distinct genotypes of both strains (identified by the genetic classification of their G protein) are predominant in any given year. This pattern is highly flexible, varies by region and may shift to other prominent genotypes the following year.[@R15] Epidemiological studies are dedicated to characterise the distribution of RSV strains and genotypes worldwide, often leading to the identification of new variants such as the RSV Thailand B strain .[@R16]

Although care of patients with RSV has been improved considerably and extensive studies have been launched to estimate viral spread and disease burden in developing countries, tremendous challenges still remain. In regard to the high prevalence, morbidity and mortality of RSV worldwide, we consider that further research and the implementation of related public health measures are crucial for future successes. However, global research funds are limited and their allocation becomes challenging. In this context, the assessment of the scientific performance is a prerequisite for the reasonable distribution of monetary support and the planning of future research endeavours by scientists interested in the field. Hence, we employed scientometric tools with the goals (1) to determine the RSV-related publication output among the extensive amount of biomedical publications and (2) to evaluate the scientific productivity of single countries in the framework of the global research landscape and in relation to socioeconomic and gender aspects. We also identified the 15 most cited landmark articles and the most prolific journals in the field of RSV research.

Methods {#s2}
=======

Methodical platform {#s2a}
-------------------

We used the NewQIS (New Quality and Quantity Indices in Science) platform to assess the worldwide RSV publication activity in a reliable and standardised way. This tool combines scientometric methods and 'density equalizing mapping projections' (DEMP)[@R17] to evaluate the publication output regarding quantitative and qualitative aspects, geographical and chronological developments, existing research networks and socioeconomic benchmarks.

Density equalising mapping {#s2b}
--------------------------

DEMP is a state-of-the-art technique to visualise benchmarking processes by anamorphic maps.[@R17] Based on the algorithm of Gastner and Newman, the size of each country was modified analogously to country-specific data on RSV research leading to a new geographic distribution of the global landscape.[@R17]

Data collection {#s2c}
---------------

For data collection, the Web of Science (WoS) Core Collection database (Thomson Reuters) was employed. The following search term was created: Title=('RSV' OR 'Respiratory Syncytial Virus' OR 'RS Virus\*') NOT Topic=(Rous Sarcoma). The Boolean operator NOT was used to exclude all publications concerning the Rous sarcoma (virus). We limited our search to original research articles. Following our protocol, the time frame was restricted from 1900 to 2013; publications in 2014 were not regarded due to incomplete data acquisition at the time the study was performed.

Data analysis {#s2d}
-------------

RSV-related articles were analysed regarding quantitative aspects such as the total number of publications, citation numbers, countries of article origin (defined as the 'country where the institution is located each author, who worked on publishing the article, is affiliated'), institutions, languages, cited reference numbers and publication date. The number of authors publishing on RSV was only quantified for the years with 30 or more annual publications. Also, h-Indices, and the average citation number per item (citation rate, CR) were investigated. Regression analysis was used to investigate the chronological evolution of RSV research. We calculated the coefficient of determination (r^2^) representing the slope of the growth in scientific output and citations.

Modified Hirsch-Index {#s2e}
---------------------

The Hirsch-Index (h-Index) is a recognised semiqualitative proxy measure to assess the impact of one author\'s research output on the scientific community.[@R21] An h-Index of 12 indicates that out of 12 published papers each has been cited at least 12 times. In this study, we applied this concept to the RSV-specific research productivity of single countries and calculated a 'modified country-specific' h-Index.

Country-specific gender analysis {#s2f}
--------------------------------

The proportionality of male and female researchers among authors publishing on RSV was analysed. Online name databases were used to identify the authors' genders.[@R23] If first names were not gender specific or quoted as initials, a manual search (using websites, corresponding addresses and social networks) was launched. We only evaluated countries where a minimum of 60 authors were affiliated and a minimum of 50% of authors were identified by gender to ensure a valid analysis. These thresholds were chosen arbitrarily based on previous studies.

Cooperation analysis {#s2g}
--------------------

We identified all RSV-associated publications that were issued due to international collaborative efforts. The total count of collaborative items was related to the overall number of publications for each investigated country. In brief, if at least two authors originating from different institutions or countries (as identified by the affiliations in the article) contributed to one article, this publication was defined as a collaborative item. Publications with two or more authors affiliated to the same country were counted one time only towards the complete count of joint publications of this particular country. If an author had two affiliations, these were counted for every country mentioned in the affiliations. Connecting vectors visualised these cooperations; their width and shade of grey reflected the number of joint publications.

Journal analysis {#s2h}
----------------

The journals publishing on RSV were analysed regarding quantitative and qualitative aspects, for example, number of published RSV articles as well as citations these items received (citation rate, CR).

Analysis of economic key figures {#s2i}
--------------------------------

Two quotients were calculated to assess the scientific output of a specific country: (1) in relation to the number of inhabitants (Q1); and (2) in relation to its economic power (as measured by the gross domestic product, GDP, Q2). Data regarding the population and GDP of investigated countries were obtained from 2012 from the CIA *World Factbook*.[@R24] We computed the quotients in the following way:Articles/population index (Q1) = number of articles/population in millionsArticles/GDP index (Q2) = number of articles/GDP in billions

All countries were classified into high-income, upper-middle-income, lower-middle-income and low-income groups according to World Bank definitions.[@R25]

We compared the total number of RSV articles to the gross domestic expenditure on Research and Development (R&D; in % of GDP) as well as to the number of researchers (per billion inhabitants) affiliated to the investigated countries.[@R26] The analysis was limited to countries that published a minimum of 30 articles in the field of RSV.

Results {#s3}
=======

Number of published items {#s3a}
-------------------------

We identified 4600 articles on RSV published between 1900 and 2013; 2645 (57.5%) of these were issued after 2000. 1960 and onwards, the number of articles increased significantly over time as indicated by r²=0.9 ([figure 1](#F1){ref-type="fig"}). A total of 10 791 authors published in the field of RSV. The number of authors per article increased by 100% in the investigated time frame. We identified a mean of 3.8 and a median of 3 authors in 1978, which was the first year with more than 30 annual publications. Ten years later, a mean of 4.59 and a median of 4 authors were found, followed by a mean of 5.05 and a median of 5 authors in 2000, a mean of 5.95 and a median of 5 authors in 2006, and a mean of 7.6 and a median of 6 authors in 2013.

![Chronological development of the number of articles.](bmjopen-2016-013615f01){#F1}

Analysis of research origin and citations {#s3b}
-----------------------------------------

Although the publications originated from 92 of the 251 investigated countries and autonomous regions, the majority of the articles were written in English (4444 articles, 96.6% of all published RSV articles), followed by French (64 articles, 1.4% of all articles) and German (32 articles, 0.7% of all articles). More than 85% of the global publication output was issued by authors from high-income economies. The USA was the most productive nation (2139 articles, 46.5% of all published RSV articles), followed by the UK (583 articles, 12.7%), the Netherlands (231 articles, 5.0%), Canada (217 articles, 4.7%) and Germany (196 articles, 4.3%). Hence, the USA and UK dominated the cartogram, while major parts of Africa (with the exception of South Africa), Asia (with the exception of Japan, China, South Korea and India) and Central America occupied only minor areas ([figure 2A](#F2){ref-type="fig"}).

![Density equalising mapping projections. (A) Number of publications. (B) Modified h-Index.](bmjopen-2016-013615f02){#F2}

The country-specific citation numbers and modified h-Indices showed a global distribution similar to the number of publications. Articles with US-American affiliation of the authors were cited most (83 000 citations, c), followed by articles from the UK (c=19 240), the Netherlands (c=5587), Canada (c=5549) and Germany (c=5319). Articles published by African, Asian and Middle American authors received hardly any citations.

The USA and the UK were the top-ranked countries with a modified h-Index of 121 (USA) and 68 (UK), followed by the Netherlands (h-Index=44), Germany (h-Index=43) and Canada (h-Index=40) ([figure 2B](#F2){ref-type="fig"}).

Regarding the country-specific CR (average number of citations per total number of publications for each country with more than 30 articles, CR), Sweden (CR=40) dominated and was followed by the USA (CR=38.8), Finland (CR=34.9), the UK and Germany (CR=27.13).

Analysis of citation performance {#s3c}
--------------------------------

The absolute citation count of all identified RSV-related articles resembled the growing volume of published papers in the investigated time frame. We documented a significant positive correlation between citation numbers and the time of publication (with r²=0.72 for the time frame from 1960 to 2008). The annual citation counts grew from 1960 to 1994 (eg, from 19 annual citations in 1960 to 2448 annual citations in 1994); after 1995, a rapid increase followed until 2003 (eg, 5274 annual citations in 1997 and 7790 annual citations in 2003) whereas a steep decline was noticed after 2006 (eg, 3147 annual citations in 2006). We identified visible peaks in citation activity for 1969 (2294 annual citations), 1986 (3898 annual citations), 2000 (7411 annual citations) and 2003 (7790 annual citations) ([figure 3](#F3){ref-type="fig"}). Additionally, we compiled the 15 most-cited RSV articles, which constitute the publications that have sparked the most documented interest in the field to date ([table 1](#T1){ref-type="table"}).

###### 

The 15 most cited articles in the area of RSV-related research are displayed including their title, publication year, countries of article origin (defined as the countries where first, senior and coauthors are affiliated), citation count and journal

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Title                                                                                                                                                                                                              Publication year   Country of article origin   Citations   Journal
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------ --------------------------- ----------- -----------------------------
  Mortality associated with influenza and respiratory syncytial virus in the United States\                                                                                                                          2003               USA                         1520        *JAMA*
  Thompson WW *et al*                                                                                                                                                                                                                                                           

  Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus\                                                                                                                       2000               USA                         856         *Nat Immunol*
  Kurt-Jones EA *et al*.                                                                                                                                                                                                                                                        

  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine\                                                                                                      1969               USA                         848         *Am J Epidemiol*
  Kim HW *et al*                                                                                                                                                                                                                                                                

  Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years\                                                                                                                          1999               Brazil, USA                 719         *Lancet*
  Stein RT *et al*                                                                                                                                                                                                                                                              

  Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants\                                                 1998               USA, Canada, UK             652         *Pediatrics*
  The Impact-RSV Study Group                                                                                                                                                                                                                                                    

  An epidemiologic study of altered clinical reactivity to respiratory syncytial (Rs) virus infection in children previously vaccinated with an inactivated RS virus vaccine\                                        1969               USA                         552         *Am J Epidemiol*
  Kapikian *et al*                                                                                                                                                                                                                                                              

  Risk of primary infection and reinfection with respiratory syncytial virus\                                                                                                                                        1986               USA                         548         *Am J Dis Child*
  Glezen *et al*                                                                                                                                                                                                                                                                

  Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7\                                                                                                  2000               Sweden, Iceland             488         *Am J Respir Crit Care Med*
  Sigurs N *et al*                                                                                                                                                                                                                                                              

  Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy\                                                                                                  1982               UK                          449         *Br Med J*
  Pullan CR and Hey EN                                                                                                                                                                                                                                                          

  Respiratory syncytial virus infection in elderly and high-risk adults\                                                                                                                                             2005               USA                         430         *NEJM*
  Falsey AR *et al*                                                                                                                                                                                                                                                             

  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children\                                                                                                1993               USA                         427         *NEJM*
  Groothuis JR *et al*                                                                                                                                                                                                                                                          

  The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection\                                                                             1981               USA                         425         *NEJM*
  Welliver RC *et al*                                                                                                                                                                                                                                                           

  Respiratory-syncytial-virus infections, re-infections and immunity---prospective, longitudinal study in young children\                                                                                            1979               USA                         418         *NEJM*
  Henderson FW *et al*                                                                                                                                                                                                                                                          

  Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter\   1999               Germany                     417         *J Virol*
  Buchholz UJ *et al*                                                                                                                                                                                                                                                           

  Asthma and immunoglobulin-e antibodies after respiratory syncytial virus bronchiolitis---a prospective cohort study with matched controls\                                                                         1995               Sweden                      416         *Pediatrics*
  Sigurs N *et al*                                                                                                                                                                                                                                                              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

![Chronological development of annual citation numbers.](bmjopen-2016-013615f03){#F3}

Relation to economic parameters {#s3d}
-------------------------------

Relating the number of publications to the population of a country, high-income countries such as Iceland (Q1=34.59), the Netherlands (Q1=13.90) and Denmark (Q1=12.25) issued a higher number of publications per million inhabitants compared with low-income or lower-middle-income countries, for example, Nigeria (Q1=0.03) and Indonesia (Q1=0.02) ([figure 4A](#F4){ref-type="fig"}). We identified two exceptions, which included the low-income countries Guinea-Bissau (Q1=6.30) and The Gambia (Q1=4.76). Both were represented among the 15 top-ranked countries in this analysis.

![Density equalising mapping projections. (A) Articles/population index (Q1). (B) Articles/GDP index (Q2) (threshold [\>]{.ul}15 articles). GDP, gross domestic product.](bmjopen-2016-013615f04){#F4}

When looking at the publication activity in relation to GDP, two low-income countries outperformed high-income nations ([figure 4B](#F4){ref-type="fig"}). Guinea-Bissau (Q2=11.776) and The Gambia (Q2=8.721) again held leading positions, followed by Iceland (Q2=0.810), Kenya (Q2=0.516) and Croatia (Q2=0.319). Besides these two exceptions, other low-income or lower-middle-income countries showed a weak performance (eg, Philippines with Q2=0.004 or Indonesia with Q2=0.007). Also, the USA did not remain under the top 10 nations and was found at position 18 (Q2=0.132).

Chile, the Netherlands, South Africa, UK and Argentina were leading the analysis when the total article count was related to the country-specific R&D expenditures (33.72, 13.32, 12.14, 11.46 and 9.56 articles per billion GDP spent on R&D, respectively). The USA dropped to position 11 with 4.52 articles per billion GDP spent on R&D ([figure 5A](#F5){ref-type="fig"}, [table 2](#T2){ref-type="table"}).

###### 

Total number of publications related to gross domestic expenditures on Research and Development in billion USD of countries that have published more than 30 items on RSV

  Rank   Country        No. of articles   R&D expenditure in % GDP   GDP in billion USD   R&D expenditure in billion USD   Articles/billion USD of R&D expenditure
  ------ -------------- ----------------- -------------------------- -------------------- -------------------------------- -----------------------------------------
   1     Chile          33                0.38                       258                  0.98                             33.72
   2     Netherlands    231               1.97                       879                  17.34                            13.32
   3     South Africa   31                0.73                       349                  2.55                             12.14
   4     UK             583               1.70                       2990                 50.85                            11.46
   5     Argentina      31                0.61                       529                  3.24                             9.56
   6     Spain          160               1.23                       1381                 17.01                            9.41
   7     Canada         217               1.61                       1783                 28.73                            7.55
   8     Denmark        68                3.08                       346                  10.67                            6.37
   9     Sweden         99                3.16                       571                  18.05                            5.49
   10    Finland        46                3,17                       272                  8.63                             5.33
   11    USA            2139              2.73                       17 348               472.78                           4.52
   12    Belgium        56                2.46                       531                  13.09                            4.28
   13    Italy          84                1.29                       2138                 27.52                            3.05
   14    Switzerland    62                2.97                       701                  20.80                            2.98
   15    France         189               2.26                       2829                 63.82                            2.96
   16    Australia      86                2.20                       1454                 31.93                            2.69
   17    Israel         33                4.11                       305                  12.53                            2.63
   18    Brazil         75                1.24                       2417                 29.87                            2.51
   19    Germany        196               2.87                       3868                 110.96                           1.77
   20    Russia         37                1.19                       2030                 24.09                            1.54
   21    Japan          192               3.58                       4596                 164.73                           1.17
   22    South Korea    36                4.29                       1411                 60.55                            0.59
   23    China\*        93                2.05                       10 351               211.79                           0.44

GDP, gross domestic product; RSV, respiratory syncytial virus; R&D, Research and Development; USD, US dollars. \*China without Taiwan.

![Density equalising mapping projections. (A) Articles/R&D expenditure in billion USD index. (B) Articles/researcher (per billion inhabitants) index (threshold  [\>]{.ul}30 articles). R&D, Research and Development; USD, US dollars.](bmjopen-2016-013615f05){#F5}

When we related the article count to the number of researchers (per billion inhabitants) as a proxy measure for the active research community working on RSV and the productivity of these researchers, the USA was leading the field (532.27 articles per researcher per billion inhabitants), followed by the UK, China, Chile and South Africa (137.10, 83.55, 77.10 and 76.60 articles per number of researchers per billion inhabitants) ([figure 5B](#F5){ref-type="fig"}, [table 3](#T3){ref-type="table"}).

###### 

Total number of publications related to articles per researcher (per billion inhabitants) of countries that have published more than 30 items on RSV

  Rank   Country        Number of RSV articles   Number of researchers per billion inhabitants   Articles/researcher (per billion inhabitants)
  ------ -------------- ------------------------ ----------------------------------------------- -----------------------------------------------
   1     USA            2139                     4.02                                            532.27
   2     UK             583                      4.25                                            137.10
   3     China\*        93                       1.11                                            83.55
   4     Chile          33                       0.42                                            77.11
   5     South Africa   31                       0.40                                            76.60
   6     Spain          160                      2.64                                            60.55
   7     Netherlands    231                      4.48                                            51.58
   8     Canada         217                      4.52                                            48.02
   9     France         189                      4.20                                            44.99
   10    Germany        196                      4.38                                            44.74
   11    Italy          84                       2.01                                            41.86
   12    Japan          192                      5.39                                            35.65
   13    Argentina      31                       1.20                                            25.79
   14    Sweden         99                       6.87                                            14.41
   15    Switzerland    62                       4.48                                            13.83
   16    Belgium        56                       4.18                                            13.41
   17    Russia         37                       3.10                                            11.93
   18    Denmark        68                       7.20                                            9.45
   19    Finland        46                       7.00                                            6.58
   20    South Korea    36                       6.90                                            5.22
   21    Israel         33                       8.26                                            4.00

RSV, respiratory syncytial virus.  \*China without Taiwan.

Country-specific gender analysis {#s3e}
--------------------------------

We identified the gender distribution among authors working on RSV in institutions affiliated to 92 countries. Our analysis indicated a larger proportion of male scientists in almost all evaluated countries ([figure 6](#F6){ref-type="fig"}). Brazil was an exception. Ninety-five authors with affiliation to Brazilian institutions were identified as working on RSV. Sixty-two of those were identifiable by name and gender. Here, men and women were almost equally represented (32 female authors, 51.6% of identifiable authors, 30 male authors, 48.4% of identifiable authors). By calculating the proportion of male to female scientists (m/f ratio), we documented the lowest ratio (m/f ratio=0.94) for Brazil, followed by Germany (m/f ratio=1.1). Japan had the highest score with m/f ratio=2.8.

![Country-specific gender analysis of the authors publishing articles referring to respiratory syncytial virus of countries (threshold: \>50% definable genders,  \>60 authors per country).](bmjopen-2016-013615f06){#F6}

International cooperation analysis {#s3f}
----------------------------------

The first collaborative article on RSV was identified in 1973. It was published by researchers working in institutions located in Switzerland and the USA.[@R27] Since 1973, a total of 614 joint articles were published on RSV accounting for 13.34% of all articles. The USA was the preferred partner for international collaborations on RSV. The most productive cooperation was established between the USA and the UK (67 joint works, 10.9% of collaborative articles), followed by the USA and Canada (45 joint articles, 7.3% of collaborative articles), and the USA and Germany (34 joint articles, 5.5% of collaborative articles).

The most fruitful cooperation not involving the USA existed between the UK and Spain (33 joint articles, 5.4% of collaborative articles). The most productive cooperation between high-income and lower-middle-income or low-income economies was set up between Kenya and the UK (18 joint articles, 2.9% of collaborative articles), followed by Guinea-Bissau and Denmark (10 joint articles, 1.6% of collaborative articles). Overall, cooperations with low-income or lower-middle-income countries were less popular ([figure 7](#F7){ref-type="fig"}).

![International cooperations on RSV research (threshold  [\>]{.ul}2 cooperations). Numbers in brackets report the number of publications in total/collaborative publications .](bmjopen-2016-013615f07){#F7}

Journal analysis {#s3g}
----------------

When we identified the most prolific journals in RSV research, the 'Journal of Virology' led the field (334 articles, CR of 45.49), followed by 'The Pediatric Infectious Disease Journal' (198 articles, CR=24.66) and the 'Journal of Infectious Diseases' (186 articles, CR 55.18) ([figure 8](#F8){ref-type="fig"}). The highest CR was achieved by the 'Proceedings of the National Academy of Sciences of the United States of America' (42 articles, CR=81.43), followed by 'Pediatrics' (66 articles, CR=70.80), 'Journal of Pediatrics' (65 articles, CR=64.03), 'American Journal of Respiratory Critical Care' (47 articles, CR=62.55) and 'Journal of Infectious Diseases' (186 articles, CR=55.18).

![Most prolific journals in the field of respiratory syncytial virus research in regard to overall publication numbers and the average citation rate.](bmjopen-2016-013615f08){#F8}

Discussion {#s4}
==========

In the WoS, we documented only 4600 RSV-related articles since 1900. The first item on the disease in humans was published in 1957.[@R28] This emphasises that research on RSV is a relatively new field considering the virus was initially isolated in 1956 from laboratory primates.[@R29] The predominance of English in the majority of identified articles aligns with the fact that this language is the recognised 'scientific lingua franca' and reflects the abundant research output of English-speaking countries such as the USA, Canada and the UK found in our study.

The increasing number of RSV publications over time is typical for most biomedical research, for example, on the John Cunningham virus, influenza or breast cancer.[@R30] Overall, the steady growth of article numbers can be explained by the rising interest in the field due to the increasing relevance of RSV in pneumonia and child mortality.[@R9] In the first few years after the detection of the virus, basic research was conducted. These endeavours, which aimed to characterise the virus, identify immunologic responses and develop vaccines, translated into a growing volume of articles on RSV.[@R32] The continuous increase since the beginning of the 1990s may be attributed to the launch of a growing number of scientific journals providing a platform for publishing. The development of modern communication systems based on new computer technologies such as the World Wide Web made it easier to communicate, exchange ideas and publicise articles in central databases. Also, it is noticeable that the increasing publication output since the 1960s was paralleled by a globally growing funding volume allocated to the R&D sector. In the USA alone, a total of US\$13 711 million was allocated to R&D in 1960 as documented by the National Science Foundation. This amount increased to US\$26 271 million in 1970 and US\$452 556 million in 2012 (<https://www.nsf.gov/statistics/2015/nsf15315/>).

The chronological development in publication quantity ([figure 1](#F1){ref-type="fig"}) was resembled by the steady increase of related citations ([figure 3](#F3){ref-type="fig"}). Four prominent citation peaks in 1969, 1986, 2000 and 2003 coincided with milestone papers in the field. In 1969, adverse effects of the formalin-inactivated RSV vaccine in children were reported.[@R36] Large epidemiological studies investigated the risks of reinfection and the mortality associated with RSV in 1986 and 2003.[@R37] The research on a prophylactic antibody licensed in 1999 and novel insights into immunologic responses involving pattern recognition receptors TLR4 and CD14 may be responsible for the peaking number of publications and citations in 2000.[@R39] The citation decline after 2006 can be attributed to the short timespan articles had allotted to receive recognition within the scientific community and obtain the appropriate citation number reflecting their true impact.[@R40] Hence, we expect this trend to be reversed in the future.

The USA dominated RSV research with regard to overall publication quantity, citation numbers and h-Index. This corresponds with a previous biomedical benchmarking study. Here, the USA was the most productive nation and authored 1 893 800 of 5 527 558 publications related to 22 organ systems from 1961 to 2007.[@R41] The leading role of the USA might be linked to major financial resources this nation dedicates to research. The US-American National Institutes of Health is by far the biggest biomedical funder in the world (eg, with a funding volume of US\$26.08 billion in 2013 compared with the biggest funding source in the European Union, the European Commission, with a funding volume of US\$3.71 billion in 2013). Also, the Department of Defense constitutes another large US-American funding organisation with a volume of US\$1.017 billion (2013), followed by private philanthropic institutions such as the Howard Hughes Medical Institute or the Bill & Melinda Gates Foundation with impressive funding volumes of US\$752.0 million (2013) and US\$462.6 million (2011), respectively.[@R42] These funds can support manpower and an outstanding scientific infrastructure illustrated by the fact that the majority of institutions working on RSV were identified in the USA, and that this nation is a preferred partner for national and international cooperations.

The cluster of the USA, Western-European countries (eg, UK or Germany) and Japan dominated the overall publication output and analyses of citation-based benchmarks. This finding corresponds with other scientometric studies (eg, on influenza, Ebola or hepatitis B).[@R30] Although Sweden and Finland published relatively low numbers of articles, they are characterised by the highest CRs in our analysis, indicating the outstanding quality and high recognition their articles received in the scientific community. Furthermore, it was striking that most African, Asian and Central American countries afflicted with a considerable RSV-related burden did not play a visible role in the field. Methodologically, we included only countries in the CR analysis that published more than 30 RSV articles aiming to generate a better validity of the investigation by avoiding overestimation of few but frequently cited articles. Nevertheless, we want to stress that the absolute number of citations as well as the CR should be viewed critically. These parameters can be affected by self-citation and inaccurate citations. Also, the Matthew effect might influence citation-based variables. Here, scientists prefer to cite articles issued by well-known researchers to papers by junior scientists leading to a disproportional increase in the related citation counts.[@R44] Hence, we also evaluated the modified h-Index since it is less influenced by outstanding, frequently or rarely cited articles skewing the CR value.[@R21] Furthermore, all citation-based variables have limitations in assessing the quality of the identified articles because they rather reflect the recognition of the research in the scientific community than measure quality.

We identified an over-representation of male authors in the majority of evaluated nations. This corresponds to the study of Head *et al* who documented the preferential funding of male researchers by UK institutions in the area of global infectious disease research. Between 1997 and 2010, funding agencies supported fewer studies of female PIs and awarded less monetary support to research supervised by women. Particularly for RSV, male researchers received five times more funding than female scientists, who spearheaded only half the funded studies compared with their male counterparts in the field.[@R46] In our gender analysis, Brazil was an exception with a majority of women authoring RSV research ([figure 6](#F6){ref-type="fig"}). This result correlates with previous investigations on yellow fever and rotavirus infections[@R47] as well as with gender benchmarking studies (eg, conducted by the 'Konrad-Adenauer Foundation' or the 'Organization for Women in Science for the Developing World'), which suggests that Brazil pioneers in the support and participation of women in science.[@R48]

Our analysis of RSV publication outputs changed in relation to economic capabilities ([figure 4](#F4){ref-type="fig"}). Two developing, low-income nations, The Gambia and Guinea-Bissau, occupied the leading positions. This finding points towards the fact that both prioritise RSV research and might be connected to existing cooperations with a long-standing shared history between collaborating nations and their focused support of RSV scientific activities. For example, the UK\'s 'Medical Research Council The Gambia Unit' and the Danish 'Bandim Health Project' encourage medical research in Guinea-Bissau and The Gambia.[@R50] Also, research in the field is promoted by single researchers with a strong dedication to conduct research in African sites. Here, Sir Brian Greenwood has spearheaded RSV-related research very successfully for decades while being faculty at the London School of Hygiene and Tropical Medicine as well as the Director of the Medical Research Council in The Gambia.[@R13]

If the RSV article counts were related to R&D expenditures and number of researchers in specific countries, a different, more refined picture emerged compared with the assessments based on absolute publication numbers or related to socioeconomic variables. Here, two Latin American countries gained importance, Chile and Argentina. It appears that these nations invest funding very efficiently in RSV research, with Chile ranked first position with 33.72 RSV articles per billion US dollars in R&D expenditures followed by Argentina in fifth position (9.56 articles per billion US dollars in R&D). Both nations' interest to fund RSV research might be linked to the fact that respiratory infections and RSV in particular impose a heavy burden on the local paediatric population. Respiratory infections constitute the second leading cause of death in Latin American children aged 5 years or below with RSV as the causative agent in 70.0% of these infections.[@R3] In the temperate climate of Chile and Argentina, RSV causes predictable outbreaks during the summer months. A particular high RSV burden of up to 70% was reported in Chilean children aged 0--11 months with lower respiratory tract infection. This was substantially higher than in other Latin American countries (eg, 18.2% in Argentina and 44% in Brazil).[@R61] Hence, RSV is constantly in the focus of the local health authorities, which routinely monitor and report the trends in RSV infections to better allocate resources for paediatric patients and limit related morbidity and mortality.[@R61]

Collaborations are becoming increasingly important in the field of RSV research as indicated by existing tight-knit networks and the growing numbers of authors per article over time. We link this development to the globalisation process, which connects scientists worldwide to exchange ideas, resources and knowledge facilitated by the growing availability of information technology. Further, it is noticeable that countries such as the USA or European Nations play a more prominent role in international collaborations compared with low-income and lower-middle-income countries. As exceptions, we could identify productive cooperations between the UK and Kenya as well as Denmark and Guinea-Bissau. The relation between Kenya and the UK might be based on their shared history and facilitated by implemented programmes such as the '*KEMRI Welcome Trust Research Program*' between the Kenya Medical Research Institute and the University of Oxford.[@R63] As revealed by Fitchett *et al*,[@R64] a substantial funding volume goes to infectious disease research in countries with colonial ties to the UK such as Kenya and The Gambia. From 1997 to 2010, these countries received £13.13 million (The Gambia) and £12.92 million (Kenya) of biomedical funding by UK-based institutions. Research activity on RSV in Guinea-Bissau is also supported by the aforementioned Danish 'Bandim Health Project,' which was founded by the anthropologist Sir Peter Aaby in the 1970s. It gathers local epidemiological data on more than 200 000 individuals. Since its foundation, this group has published more than 600 items on vaccines, maternal mortality and childhood infections such as RSV.[@R50]

Timing, intensity and clinical impact of RSV infections vary worldwide.[@R3] Hence, research is still needed to alleviate the burden related to RSV in high-risk populations. Interventions should focus on data collection via established surveillance systems (eg, aiming to define local morbidity and mortality, assist disease modelling and guide prophylactic measures and vaccine development).[@R65] In this context, our study revealed a striking discrepancy in scientific productivity and collaborative involvement between high-income and low-income countries. Also, attention should be drawn to a further problem concerning low-income nations or countries whose researchers have a limited financial budget to pay for publication in renowned open access journals. This issue increases the apparent discrepancies regarding publication activities even further. To minimise this problem, a number of waiver programmes currently exist, that is, for journals such as *PLOS*, *Biomed Central* or *BMJ OPEN*,[@R66] but these should be expanded more broadly. However, we can deduce from our findings that developing nations---although experiencing the most significant consequences of RSV epidemics---cannot compete equally in the field of RSV research due to the lack of funding and infrastructure. Therefore, we want to emphasise the need---an almost ethical responsibility---to involve these nations in funding programmes and successful international collaborations as seen for Guinea-Bissau, Kenya and The Gambia. We acknowledge that the establishment of collaborations between high-income and low-income nations is challenging due to the lack of resources, manpower and funding opportunities, the political climate, cultural differences between the potential partners, and an unrealistic assessment of the local research capacity and resources.[@R69] Also, existing collaborations and funding streams need to be viewed critically since they should rather reflect local disease burden, apparent healthcare disparities and scientific capability than being allocated based on a shared language or history between countries (eg, guided by former colonial ties). Therefore, funding institutions should revise their policies appropriately.[@R64] Also, global investment surveillance systems need to be established such as the 'Research Fairness Initiative' led by Cohred to guide and monitor sustainable, transparent and effective partnerships in research (<http://rfi.cohred.org/origin-of-the-rfi/>). Nevertheless, tight-knit networks would be key for developing countries to participate in the international exchange of data, resources and knowledge, and to facilitate their involvement in high-quality research efforts despite an unequal starting point.

Study limitations {#s4a}
-----------------

Our study has several limitations. Using the WoS to conduct this analysis is associated with an important strength and with a weakness of the study. The WoS enabled us to assess quantitative and qualitative aspects of the publication output related to RSV research. This is a unique feature allowing a multifaceted evaluation of the publication productivity. On the other hand, the WoS displays a strong preference for English journals. Therefore, not all articles ever published on RSV could be analysed here. However, we regard this bias as limited as the majority of high-quality data are commonly published in international journals indexed by the WoS and therefore definitely included in our search. Also, we acknowledge that not all eligible RSV publications were detected by the conducted 'TITLE' search. This approach was preferred to a 'TOPIC' search, which identifies the search term in the abstract and the keywords leading to a significant amount of off-topic publications compromising the validity of our data collection. We concentrated our study on original articles to focus on published 'cutting edge research' in the field of RSV. We acknowledge that this strategy narrowed down the focus on the topic since other publication types such as commentaries, reviews, case reports or meeting reports were not included. Further, we did not employ any additional platforms such as PubMed, Google Scholar or Scopus to collect bibliometric data because the management, organisation and the scope of data are slightly different among these databases. This would affect triangulating, comparing and integrating data related to RSV research in a meaningful way.

We identified the first collaborative article on RSV in 1973, which would indicate that researchers from different countries did not work together on RSV before this point in time. This assumption is not necessarily true. In 1972, the WoS indexed author affiliations for the first time, which indicates that articles published in a joint effort before 1972 would not have been detected by our methodological approach. The evaluation of country-specific publication performance by gender is meaningful but should be evaluated critically. Not all first names were included in our analysis since some were gender neutral, not listed in name databases or displayed as initials. Therefore, the threshold of at least 60 publishing scientists and 50% gender definability was implemented to include only countries providing meaningful and valid data. Further, we identified 'Mortality associated with influenza and respiratory syncytial virus in the United States' by Thompson *et al* as the most cited journal article in the field of RSV. It received 1520 citations representing its outstanding recognition in the scientific community. The publication covers the topics RSV as well as influenza, so the limitation has to be mentioned that our computed approach did not differentiate if the article was cited in 'influenza' or 'RSV' papers. Employing a manual analysis, we found that 70.3% of citing articles can be attributed to influenza, only 15.8% to RSV, and 2.2% were covering both topics. Hence, the impact of this particular paper on the field of RSV must be considered as less than it initially appeared based on the citation count alone.

Conclusion {#s4b}
----------

We evaluated the worldwide RSV-related research output and demonstrated large differences between high-income, middle-income or low-income nations regarding most scientometric variables. These discrepancies partly diminished when country-specific scientific activities were related to economic key measures; here, the leading position of the USA in science was challenged by other nations. Hence, calculating these quotients is beneficial for the comparison of countries with unequal conditions and different scientific infrastructures. However, we can deduce from our study that research efforts of middle-income or low-income nations have to be strengthened, for example, by the reduction of journal fees and inclusion in international collaborations, so apparent disparities can be minimised and higher mortality rates related to RSV in developing nations can be tackled successfully.
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